FLIXONASE Nasal drops Ref.[27691] Active ingredients: Fluticasone

Source: Medicines & Healthcare Products Regulatory Agency (GB)  Revision Year: 2019  Publisher: Glaxo Wellcome UK Limited, trading as Allen & Hanburys, 980 Great West Road, Brentford, Middlesex, TW8 9GS

4.1. Therapeutic indications

Flixonase Nasule Drops are indicated for the regular treatment of nasal polyps and associated symptoms of nasal obstruction.

4.2. Posology and method of administration

Posology

The dose should be titrated to the lowest dose at which effective control of disease is maintained.

For full therapeutic benefit regular usage is essential. The absence of an immediate effect should be explained to the patient as maximum relief may not be obtained until after several weeks of treatment. However, if no improvement in symptoms is seen after four to six weeks, alternative therapies should be considered.

Unilateral polyposis rarely occurs, and could be indicative of other conditions. Diagnosis should be confirmed by a specialist.

Adults

The contents of one container (400 micrograms) to be instilled once or twice daily. The dose should be divided between the affected nostrils.

Elderly

The normal adult dosage is applicable.

Paediatric population

There are insufficient data at present to recommend the use of fluticasone propionate for the treatment of nasal polyps in children less than 16 years.

Method of administration

Flixonase Nasule Drops are for administration by the intranasal route only, contact with the eyes should be avoided.

After shaking and opening the container, the patient should adopt one of the positions outlined in the patient information leaflet. The dose should be divided between the nostrils by either counting approximately 6 drops into each nostril or by holding the dimpled sides of the container and squeezing once into each nostril (one squeeze delivers approximately half the dose).

Full instructions for use are given in the patient information leaflet.

4.9. Overdose

There are no data available from patients on the effects of acute or chronic overdosage with Flixonase Nasule Drops.

In healthy volunteers, intranasal administration of 2 milligrams fluticasone propionate twice daily for seven days had no effect on hypothalamic-pituitary-adrenal axis (HPA) function. Administration of doses higher than those recommended over a long period of time may lead to temporary suppression of the adrenal function. In these patients, treatment with fluticasone propionate should be continued at a dose sufficient to control symptoms; the adrenal function will recover in a few days and can be verified by measuring plasma cortisol.

6.3. Shelf life

3 years.

After removal of foil: 28 days.

6.4. Special precautions for storage

Do not freeze.

Keep the containers in the outer carton.

Store upright.

Do not store above 30°C.

6.5. Nature and contents of container

Strips of polyethylene single dose (400 micrograms) containers, within foil wrapping are available in the following pack sizes:

28 containers (4 strips of 7 Nasules)

84 containers (12 strips of 7 Nasules)

Not all pack sizes may be marketed.

6.6. Special precautions for disposal and other handling

No special requirements.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.